Head to Head

bmiMD vs Found

Both put their best rate behind a prepaid year, and they differ on what the year buys: a published ladder and a named operating entity at bmiMD, a refund policy and brand-name access at Found.

At a glance

bmiMD and Found, compared on 10 points
Compared onbmiMDFound
Pricing structureA published ladder keyed to plan length; within any term the rate holds across dosesOne flat program price covering either compound, holding across doses
Plan commitmentThe lowest rung requires a twelve-month prepayment; monthly billing sits well above itTwelve months prepaid for the advertised rate; month-to-month billing costs substantially more
Cancellation and refundsA non-refundable fee applies if you cancel after intake is approvedA specific refund policy is published for the membership fee
Charge at checkoutDescribed as an authorization hold, released with no charge if a provider declines the patientNot published as a hold; the membership refund policy is what is published instead
Brand-name optionNone publishedWegovy, Ozempic, Zepbound, and Mounjaro, each at its own listed price
Tirzepatide premiumPriced above semaglutide on the published ladderNo premium — the same program price covers either compound
Who is behind the brandOperated by Medccm Inc., disclosed on the site, with a public Trustpilot profileDisplays a LegitScript seal and states BBB accreditation, both published claims
Compounding pharmacyNot namedNot named; described only by the 503A licensing class
States servedAll fifty statesAll fifty states
Disclosure score5.0/107.5/10

What each one publishes

Every price bmiMD and Found publish, with each figure's own qualifier and verification date
MedicationbmiMDFound
Semaglutide (brand)Not published$650/mostarting at, per monthWegovy · Verified August 2026 source
Semaglutide (compounded)$119/moper month, 3-month planflat rate, all doses · Verified August 2026 source$169/moper month, 12-month prepaid planflat rate, all doses · Verified August 2026 source
Tirzepatide (brand)Not published$650/mostarting at, per monthZepbound · Verified August 2026 source
Tirzepatide (compounded)$179/moper month, month-to-monthflat rate, all doses · Verified August 2026 source$169/moper month, 12-month prepaid planflat rate, all doses · Verified August 2026 source

Two prepaid years, two different structures

bmiMD sells on a ladder keyed to plan length. Each longer prepaid term buys a lower monthly rate, and within any chosen term the rate holds as the dose climbs. There is also a newer lower-dose product line on the same structure.

Found does not run a ladder. It publishes one flat program price that covers either compound, with the advertised rate gated behind prepaying twelve months.

What bmiMD does unusually well is publish the rungs. A reader can see what each term costs and do the arithmetic before handing over a card, rather than meeting the structure at checkout. A ladder is also a device designed to make the longest term look obviously correct, so read the rungs as what they are: a discount for accepting risk the provider would otherwise carry.

What leaving costs at each

bmiMD charges a non-refundable fee to cancel once intake has been approved. It is disclosed rather than hidden, and it is small next to a course of treatment. It also lands at the exact point a patient would want to change their mind.

Found publishes a specific refund policy for its membership fee, which is more than most of this field commits to in writing. Read that policy against the twelve-month prepaid term before deciding, because the two terms interact.

bmiMD offers a counterweight at the other end. It describes the charge taken at checkout as an authorization hold, released without a charge if a provider declines the patient. That addresses a common grievance in this category: being billed before anyone has confirmed eligibility.

Which drug you want changes the arithmetic

Across this category tirzepatide usually costs more than semaglutide, and bmiMD's ladder follows that pattern.

Found's flat program price covers either compound. A patient who wants tirzepatide from the start avoids the premium, and one who switches later does not walk into an increase.

So Found looks strongest on tirzepatide and less distinctive on semaglutide, where bmiMD's ladder is competitive and legible. Check which compound a figure belongs to before treating it as a verdict on either provider.

Only one of these sells an approved product

Found sells brand-name GLP-1s on a separate track from its compounded program, each at its own listed price. bmiMD publishes compounded products only.

A compounded preparation is made by a compounding pharmacy and has not been through the FDA approval process a brand-name GLP-1 has. Those are two different purchases, and most of the price gap between them is explaining itself.

Found's own pricing pages state different starting points for brand-name medication, and the gap is wide. That discrepancy is reported rather than resolved, because resolving it would mean picking one of the company's own numbers. Get a brand-name figure in writing for your own situation.

How much each tells you about itself

bmiMD discloses that it is operated by Medccm Inc. A meaningful share of telehealth GLP-1 brands are marketing names attached to an entity a customer cannot identify, which leaves a patient nowhere to go past customer service. bmiMD also maintains a public Trustpilot profile, which is a place to read complaints rather than a rating worth endorsing.

Found displays a LegitScript seal and states BBB accreditation. Both are published claims. A seal on a page establishes that a seal is published, not who holds the underlying certificate, and it is not converted into one here.

Neither names the pharmacy that compounds the medication. Found stops at the 503A licensing class, which is a category rather than an identity. On the disclosure that matters most for a compounded product, both fall short.

So which one

It depends on which of these matters more to you. If you want a brand-name, FDA-approved option available behind the same account, or tirzepatide without a premium, only Found offers either.

If you want to see every rung of the pricing before committing, and to know which legal entity you are dealing with, bmiMD publishes more of what you would be signing. Weigh its cancellation fee honestly against Found's published refund policy — that pairing, not the headline figures, is the real trade.

Boards both of these appear on

bmiMD and Found both qualify for 4 of the 6 boards on this site. Each board ranks a wider field than these two, so a position here is against everyone on it, not against each other.

Who each one is better for

bmiMD

  • Readers who want the whole plan-length ladder published so they can run the arithmetic before committing.
  • Patients who will not deal with a brand that hides its operating entity, and who want an outside review venue to read complaints in.
  • People who want the assurance that a declined intake releases the hold rather than charging the card.

Found

  • Readers still deciding between a compounded preparation and a brand-name, FDA-approved GLP-1 who want both behind one intake.
  • Patients who want tirzepatide without the premium most providers in this comparison attach to it.
  • Readers who want a published refund policy for the membership fee rather than a cancellation fee at the same point in the process.

Frequently asked questions

Both want a prepaid year. What is the actual difference?

What the year buys. At bmiMD it buys the bottom rung of a published ladder, with every rung visible so you can price shorter terms yourself. At Found it buys one flat program price that covers either compound, plus access to a brand-name track bmiMD does not have. The exit terms differ too: bmiMD charges a non-refundable fee to cancel after intake approval, while Found publishes a specific refund policy for its membership fee. Read those two terms side by side before the headline figures.

What happens if I cancel?

At bmiMD, a non-refundable fee applies once your intake has been approved. It is disclosed and it is small relative to a course of treatment, but it applies at the moment most people would want to change their mind. Found publishes a specific refund policy covering its membership fee, which is unusual in this field. Neither term should be read on its own — pair each with the twelve-month prepayment sitting underneath the advertised rate.

Can I get Wegovy or Zepbound from either?

Only from Found, which sells the brand-name products alongside its compounded program, each at its own listed price. bmiMD publishes compounded products only. Be careful with the brand-name figure: Found's own pages state different starting points for it, and the gap between them is wide, so confirm a price directly for your own situation before relying on it.

Does either name the pharmacy that compounds the medication?

No. bmiMD names its operating entity, Medccm Inc., but never the pharmacy. Found describes its pharmacies only by the 503A licensing class, which tells you the kind of pharmacy rather than the one filling your order. On a compounded medication that is the disclosure most worth having, and neither provider supplies it. At least one other provider in this comparison names more than one pharmacy outright.

Will I be charged before anyone confirms I am eligible?

bmiMD says the amount taken at checkout is a hold rather than a collection, and that nothing is charged if a provider turns you down. That addresses one of the more common complaints in this category. Found publishes a membership refund policy instead, which covers a different moment in the process. Confirm the specifics with either company for your own order rather than assuming the two arrangements are equivalent.